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A report on the Critical Assessment of Microarray Data
Analysis (CAMDA’03) meeting and competition, Durham,
USA, 12-14 November 2003.
The CAMDA meeting was started in 2000 by Simon Lin and
Kimberly Johnson (Duke University Bioinformatics Shared
Resource, Durham, USA). Patterned on the molecular mod-
eling community’s well-known Critical Assessment of Tech-
niques for Protein Structure Prediction (CASP) experiment
and related competitions in genomics, statistical genetics
and computational toxicology, it allows participants to
present analyses of common datasets to display novel
methodology and results. All the speakers present an analy-
sis of the same data, helping the audience gain an under-
standing of current capabilities and problems in the field.
Conferences in previous years have concentrated on large
datasets from experiments with model organisms. The
added challenge of this year’s competition was the provision
of multiple clinical microarray datasets, with associated epi-
demiological information to heighten the stakes. 
The organizers of this year’s CAMDA meeting and competi-
tion [http://www.camda.duke.edu] had selected four lung
cancer expression-profile databases as the data sources
(Table 1), which had sparked clinical and pharmaceutical
interest in addition to highlighting the latest approaches in
microarray data mining. Over 150 statisticians, computer
scientists, and biologists presented their analyses of the fea-
tured datasets. Jeffrey Morris (MD Anderson Cancer Center,
University of Texas, Houston, USA) and his group were
voted as winners by the audience for their approach to inte-
grating data across different Affymetrix datasets (see below
for details).
Relating critical assessment of microarray data analysis to
clinical outcome for the deadliest of human cancers has been
of particular interest to those profiling lung cancer. Despite
more than 400 publicly available lung cancer expression
profiles, the results so far have raised as many questions as
answers. Many studies have clearly demonstrated correla-
tions between expression profile and clinical outcome, but
most of the gene sets that have been identified in this way
have frustratingly little overlap with each other. The increas-
ing volume of available data has not made the picture any
clearer. The development of new methods for data mining,
particularly when the data are analyzed in the context of
associated clinical information, promises new inferences
from existing data and may help to derive a true molecular
system for further refining the stages of lung cancer.
Morris focused on the Affymetrix datasets from Michigan
and Harvard (see Table 1) in an attempt to generate a
Table 1
Data sources for CAMDA’03 
Abbreviation Reference
used here
Affymetrix data Harvard Bhattacharjee et al., 
Proc Natl Acad Sci USA 2001, 
98:13790-13795. 
Michigan Beer et al., Nat Med 2002, 
8:816-824.
cDNA spotted  Stanford Garber et al., Proc Natl Acad 
microarray data Sci USA 2001, 98:13784-13789.
Ontario Wigle et al., Cancer Res 2002, 
62:3005-3008.meta-analysis of the combined data. He proposed a novel
approach to the problem of analyzing two datasets in con-
junction, even when they are on different versions of the
Affymetrix human chip. Probe sets common to each array
were identified and the data were combined for 4,101 differ-
ent unigenes. Further filtering removed half the genes with
the lowest mean expression levels across all samples, as well
as genes with small standard deviations across the samples,
to leave 1,036 genes for consideration. Multivariable Cox
models were constructed for each of the 1,036 probe sets to
look for genes providing prognostic information. A total of
26 genes were identified as predictors of patients’ survival.
Interestingly, none of these genes appeared in the list of the
top 100 genes from the Michigan analysis, and only one was
mentioned in the Harvard paper.
Two presentations from researchers at GlaxoSmithKline
(GSK) also focused on a meta-analysis of the two Affymetrix
datasets. They presented slightly different strategies, possibly
representing views from research centers on different sides of
the Atlantic. Xiwu Lin (GSK Biomedical Data Sciences Group,
Collegeville, USA) integrated the data using both gene names
and probe-set IDs. Initial principal component analysis
revealed the two datasets to be completely non-overlapping,
demonstrating the importance of normalization before
further integrated analysis. A number of genes were shown to
partition patients into groups with a high or low chance of
survival, using the tree method for analyzing survival data in
relation to significant genes identified by Cox modeling.
These genes included NME2 (encoding nucleoside diphos-
phate kinase B, a protein expressed in non-metastatic cells),
B2M (2-microglobulin),  HSF1  (heat-shock transcription
factor 1) and PGK1 (phosphoglycerate kinase 1), the last of
which has been recently identified in a number of genomic
and proteomic studies as a potential indicator of cancer prog-
nosis. Linda Robb (GSK Statistical Sciences Group, Steve-
nage, UK) discussed an approach that explores the data using
principal component analysis before survival analysis and
then uses Cox modeling for each gene to link variables associ-
ated with survival. Fisher’s combined probability test (Fish-
er’s meta-analysis) was used to combine p-values from the
two analyses and to define a new modified p-value for the
association of every gene with survival. This resulted in 33
genes with an adjusted p-value < 0.05. Many of these genes
were not identified in the original publications.
In one of the few presentations that considered the data
derived from spotted cDNA arrays (see Table 1), Geoff
McLachlan (University of Queensland, Brisbane, Australia),
showed evidence from the Stanford and Ontario studies that
suggested that clustering of gene-expression data according
to prognosis may be a more powerful predictor of disease
outcome than current staging systems based on histopathol-
ogy or extent of disease at presentation. Using the EMMIX-
GENE algorithm developed by himself and colleagues
[http://www.maths.uq.edu.au/~gjm], McLachlan was able
to identify genes correlated with clinical outcome. As with
other analyses presented at the meeting, however, these
genes did not appear to overlap well with ones identified in
the original publications. 
Overall, many presenters agreed that trying to combine data
across different platforms to perform true meta-analyses
was largely futile for anything other than the Affymetrix
datasets. Even for these arrays, there are considerable chal-
lenges in trying to work across two different versions of the
Affymetrix human gene chip. Spotted cDNA array data has
the added challenge of variations in array construction,
choice of reference RNA, data-normalization strategy and
the extent of missing data, to name but a few of the possible
variables. Despite this, Neil Hayes (Tufts University, Boston,
USA) showed an interesting approach to data integration by
creating ratios from Affymetrix data using gene-expression
values from the reference samples used in the Stanford
study. Whether such an approach will be robust enough for
application to other cDNA studies remains to be determined.
Unfortunately, integrative analysis has shown that the gene
overlap for the platforms used in the four datasets is sober-
ingly low (the number of overlapping genes on the four
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Figure 1
Combining the four different microarray platforms used in the CAMDA
competition gives 2,449 genes in common. The platforms used were
Affymetrix HG-U95 (Harvard, with 12,600 probe sets), Stanford spotted
arrays (with 23,100 clones), Toronto OCI 19k2 spotted arrays (Ontario,
with 19,200 clones), and Affymetrix HuGeneFL (Michigan, with 7,129
probe sets). See Table 1 for references.
Harvard
12,600
Stanford
23,100
2,499
Ontario
19,200
Michigan
7,129platforms used is shown in Figure 1). This is both good and
bad news. The good news is that each study increases the
overall search space for markers; the bad news is the limited
chance for overlap in the set of differentially identified
genes. Further complicating the picture in clinical studies is
the potential for differences between tissue samples, which
results in a further reduction in the chance of identifying
overlapping markers. 
The meeting also showed that computationally derived
markers, even from multiple analyses on multiple datasets,
clearly do not provide the level of confirmation necessary to
translate into clinical utility. One can validate results in
three ways: using different methodology, such as reverse-
transcriptase PCR (RT-PCR), but still on the same RNA or
tumor samples; using the same method but on different
samples (such as more arrays on different tumors or
patients); or using different method(s) on different samples.
Only the third of these will provide validation that is consid-
ered adequate to translate into broad clinical impact. 
Looking to the future, thoracic oncologists eagerly await data
from the National Cancer Institute’s Director’s Challenge,
which plans to collect and analyze Affymetrix data on over
600 lung cancer samples from multiple centers with associ-
ated clinical information in what will be the largest clinical
microarray study to date in any tumor type. We hope this
will provide clearer answers on which correlations between
gene expression and clinical outcome are valid, so that iden-
tified markers can be incorporated into future clinical trials.
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